Aisle7 launches new programs to manage store planning
PORTLAND, Ore. Aisle7 (formerly Healthnotes), will unveil its new flagship product: Aisle7 IN-STORE 2009 on Tuesday, the company announced.
Featuring interactive shopping guides, easy-to-use shopping tools and a new suite of applications, retailers are able to engage shoppers on several top-of-mind issues for the consumer, notably wellness, sustainability and saving money.
Aisle7 IN-STORE 2009 features a new campaign-driven architecture allowing retailers to create unique wellness campaigns that match their own marketing calendars and allow them to deliver relevant shopping ideas and targeted messages in high-margin departments throughout the store.
“Shopper marketing is the fastest growing segment of retailers’ marketing budgets and grocers are in need of flexible, customizable, storewide programs that can amplify their marketing messages and brand,” stated Jeffrey Beyer, Aisle7 chief executive officer. “Our solutions help retailers capitalize on this growing trend by inspiring new ideas and driving incremental sales.”
To help retail marketers engage shoppers, align marketing initiatives and leverage existing investments, Aisle7 IN-STORE 2009 provides a new suite of applications and customization options that extend the base program, including:
• Aisle7 Brand allows retailers to customize programming and directly integrate marketing initiatives for additional leverage and consistency;
• Aisle7 Promote delivers a contextual marketing solution to promote private label, store programs and promotions alongside engaging, relevant content;
• Aisle7 Scan provides shoppers relevant product information, product tips and cross-sell suggestions with a simple bar code scan;
• Aisle7 Locate allows shoppers to locate products throughout the store through an integrated planogram;
• Aisle7 Target integrates with retailers’ existing loyalty programs to present shoppers with targeted shopping ideas, offers and wellness tips.
“In today’s competitive environment, retailers need to make it easy to connect shoppers with their products,” added Robert Johnson, president of TreoSystems. “We are excited to be working with Aisle7 to offer retailers integrated item locator solutions to help shoppers find the products they’re looking for, along with relevant promotions and cross-sell recommendations that can drive additional sales.”
CHPA initiates safety study into dosing, efficacy of children’s cough-cold medicines
WASHINGTON Following an all-day public meeting Thursday held by the Food and Drug Administration regarding the appropriateness of marketing cough-cold products with scant pediatric data supporting safety and efficacy for children under the age of six, the Consumer Healthcare Products Association announced its progress in delivering safety and efficacy clinical trials for this category.
To date, CHPA has put together a comprehensive efficacy and safety program for children age two to under 12, including pharmacokinetic studies to confirm the dosing for the eight most commonly used OTC oral cough and cold ingredients. Once these dosing studies are finalized, CHPA plans to begin research on revalidating the effectiveness of these medicines.
In addition, CHPA stated it would continue to collect and review all available safety data around these medicines. “A comprehensive safety review in 2007 and data from the U.S. Centers for Disease Control and Prevention show that the majority of adverse events associated with OTC oral pediatric cough and cold medicines are a direct result of accidental ingestion,” noted Linda Suydam, CHPA president. “Reducing these preventable errors is the cornerstone of CHPA’s national educational program.”
CHPA will also continue its national education program that focuses on the root causes of adverse events and speaks directly to parents, day care providers, healthcare providers and other caregivers.
CHPA is partnering with a number of organizations in these efforts, including the American Pharmacists Association and the American Association of Family Physicians.
Vitamin C may impact efficacy of certain cancer drugs, journal says
PHILADELPHIA Vitamin C may interfere with the efficacy of several cancer drugs in mice, the journal Cancer Research reported Wednesday, including doxorubicin, cisplatin, vincristine, methotrexate and imatinib.
“These results support the hypothesis that vitamin C supplementation during cancer treatment may detrimentally affect therapeutic response,” the authors concluded.